Multicentre retrospective cohort study assessing the incidence of serious infections in patients with lupus nephritis, compared with non-renal systemic lupus erythematosus

被引:1
|
作者
Yates, Drew Joseph [1 ]
Mon, Saw Yu [2 ]
Oh, Yumi [3 ]
Okano, Satomi [4 ]
Manickam, Valli [5 ]
Soden, Muriel [6 ]
Kubler, Paul [1 ]
Ranganathan, Dwarakanathan [2 ]
机构
[1] Royal Brisbane & Womens Hosp, Rheumatol, Herston, Qld, Australia
[2] Royal Brisbane & Womens Hosp, Renal Med, Herston, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Internal Med, Herston, Qld, Australia
[4] QIMR Berghofer Med Res Inst, Stat Unit, Herston, Qld, Australia
[5] Townsville Hosp, Renal Med, Townsville, Qld, Australia
[6] Townsville Hosp, Rheumatol, Townsville, Qld, Australia
来源
LUPUS SCIENCE & MEDICINE | 2020年 / 7卷 / 01期
关键词
lupus nephritis; systemic lupus erythematosus; infections; corticosteroids; DISEASE-ACTIVITY; HOSPITALIZED-PATIENTS; RISK; INDEX;
D O I
10.1136/lupus-2020-000390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The incidence of serious infections is poorly defined in patients with lupus nephritis (LN). It is also unclear if LN influences risk of serious infections in a longitudinal analysis. The aim of this study was to determine the incidence of serious infections in patients with SLE and LN, compared with patients with SLE without LN. Methods A multicentre retrospective cohort study was conducted. Patients with LN identified at two tertiary centres were matched where possible with age and gender-matched patients with SLE without LN. Any infection requiring inpatient admission, occurring in the 6 months following index clinical visit, was considered serious. Cox regression was employed to investigate the association between risk of serious infection and LN status, and other relevant covariates. Results A total of 173 patients were included within the analysis (n=87 LN, n=86 SLE only). A total of 9.2% (n=8) of patients with LN experienced at least one serious infection within the study period, compared with 5.8% (n=5) of patients without LN, equivalent to 19.5 and 12.0 infections per 100 patient-years with and without LN, respectively. Univariable and multivariable analyses found no significant increased risk of serious infection in patients with LN versus controls (HR 1.61; 95% CI 0.53 to 4.92 and adjusted HR (aHR) 0.91; 95% CI 0.27 to 3.06, respectively). Increased prednisone dose and modified SLE comorbidity index were strongly associated with serious infection (aHR (per 5 mg) 1.21; 95% CI 1.07 to 1.37; p=0.003 and aHR 1.13; 95% CI 1.02 to 1.25; p=0.018, respectively). Conclusions In this cohort, adjusting for cofactors, the presence of LN alone does not appear to increase the risk of serious infections compared with patients with SLE without LN. However, increased prednisone dose at baseline visit and increasing comorbidity were independently associated with the incidence of serious infection.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] PREVALENCE OF FIBROMYALGIA IN A COHORT OF RENAL AND NON-RENAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
    Almathkouri, Ammar
    Pyne, Dev
    Rajakariar, Ravindra
    Cove-Smith, Andrea
    Lewis, Myles
    Pakozdi, Angela
    [J]. RHEUMATOLOGY, 2019, 58 : 196 - 196
  • [2] Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study
    Hermansen, Marie-Louise F.
    Lindhardsen, Jesper
    Torp-Pedersen, Christian
    Faurschou, Mikkel
    Jacobsen, Soren
    [J]. JOURNAL OF RHEUMATOLOGY, 2016, 43 (07) : 1335 - 1339
  • [3] RITUXIMAB FOR THE TREATMENT OF NON-RENAL SYSTEMIC LUPUS ERYTHEMATOSUS
    Cobo-Ibanez, T.
    Loza-Santamaria, E.
    Pego Reigosa, J. M.
    Calvo-ALen, J.
    Rosario-Lozano, M. P.
    Rua-Figueroa, I.
    Munoz-Fernandez, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 254 - 254
  • [4] Serious infections in patients with systemic lupus erythematosus
    Goldblaft, F.
    Rahman, A.
    Isenberg, D. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 464 - 465
  • [5] Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis
    Feldman, Candace H.
    Hiraki, Linda T.
    Winkelmayer, Wolfgang C.
    Marty, Francisco M.
    Franklin, Jessica M.
    Kim, Seoyoung C.
    Costenbader, Karen H.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67 (06) : 1577 - 1585
  • [6] Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan
    Nakano, M.
    Kubo, K.
    Shirota, Y.
    Iwasaki, Y.
    Takahashi, Y.
    Igari, T.
    Inaba, Y.
    Takeshima, Y.
    Tateishi, S.
    Yamashita, H.
    Miyazaki, M.
    Sato, H.
    Kanda, H.
    Kaneko, H.
    Ishii, T.
    Fujio, K.
    Tanaka, N.
    Mimori, A.
    [J]. LUPUS, 2019, 28 (09) : 1062 - 1073
  • [7] Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus. an Observational Cohort Study
    Tselios, Konstantinos
    Gladman, Dafna
    Su, Jiandong
    Urowitz, Murray
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] HERPES ZOSTER INCIDENCE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE COHORT STUDY
    Stempniewicz, N.
    Steffens, A.
    Kim, K.
    Jorga, A.
    Bell, C.
    Ducharme, M.
    Trenz, H.
    Singer, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1108 - 1109
  • [9] SPLENIC FUNCTION IN NON-RENAL SYSTEMIC LUPUS-ERYTHEMATOSUS
    ELKON, KB
    SEWELL, JR
    RYAN, PFJ
    HUGHES, GRV
    [J]. AMERICAN JOURNAL OF MEDICINE, 1980, 69 (01): : 80 - 82
  • [10] RENAL BIOPSY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: IS IT ONLY LUPUS NEPHRITIS?
    Duran, E.
    Yildirim, T.
    Kalyoncu, U.
    Taghiyeva, A.
    Bilgin, E.
    Saglam, E. Arzu
    Uner, M.
    Jabrayilov, J.
    Bolek, E. C.
    Onal, C.
    Farisogullari, B.
    Koc, N. S.
    Yardimci, G. K.
    Girgin, S.
    Ayan, G.
    Ozsoy, Z.
    Uzun, G. Sandal
    Kilic, L.
    Yilmaz, S. R.
    Akdogan, A.
    Bilgen, S. A.
    Karadag, O.
    Kiraz, S.
    Altun, B.
    Erdem, Y.
    Arici, M.
    Ertenli, A. I.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1198 - 1199